Formoterol and Cancer Muscle Wasting in Rats: Effects on Muscle Force and Total Physical Activity

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2012 Sep 15

PMID 22977567

Citations 8

Authors

Silvia Busquets

Miriam Toledo

Sonia Sirisi

Marcel Orpi

Roberto Serpe

Joana Coutinho

Raquel Martinez

Josep M Argiles

Francisco J Lopez-Soriano

Affiliations

Soon will be listed here.

Abstract

Cancer cachexia occurs in the majority of cancer patients before death, and it is responsible for the death of 22% of cancer patients. One of the most relevant characteristics of cachexia is that of asthenia, which reflects significant muscle wasting noted in cachectic cancer patients The aim of the present study was to assess whether the β(2)-adrenergic agonist formoterol is associated with an improvement in physiological parameters such as grip force and total physical activity in cachetic rats. Administration of the β(2)-agonist formoterol (0.3 mg/kg for 7 days) in rats bearing Yoshida AH-130 ascites hepatoma tumors, a model which induces a strong loss of both body and muscle weight, resulted in a significant reversal of the muscle wasting process, as reflected by individual muscle weights. The anti-wasting effects of the drug were also observed in terms of total physical activity and grip force, thus resulting in an improvement in physical performance in cachectic tumor-bearing rats.

Citing Articles

Formoterol reduces muscle wasting in mice undergoing doxorubicin chemotherapy.

de Lima Junior E, Teixeira A, Silveira L, Jove Q, Ladron N, Pereira M Front Oncol. 2024; 13:1237709.

PMID: 38234397 PMC: 10791811. DOI: 10.3389/fonc.2023.1237709.

Unraveling the lost balance: Adrenergic dysfunction in cancer cachexia.

Diba P, Sattler A, Korzun T, Habecker B, Marks D Auton Neurosci. 2023; 251:103136.

PMID: 38071925 PMC: 10883135. DOI: 10.1016/j.autneu.2023.103136.

Pharmaceutical Agents for Contractile-Metabolic Dysfunction After Volumetric Muscle Loss.

Mcfaline-Figueroa J, Schifino A, Nichenko A, Lord M, Hunda E, Winders E Tissue Eng Part A. 2022; 28(17-18):795-806.

PMID: 35620911 PMC: 9634984. DOI: 10.1089/ten.TEA.2022.0036.

Phenotypic features of cancer cachexia-related loss of skeletal muscle mass and function: lessons from human and animal studies.

Martin A, Freyssenet D J Cachexia Sarcopenia Muscle. 2021; 12(2):252-273.

PMID: 33783983 PMC: 8061402. DOI: 10.1002/jcsm.12678.

Lack of Synergy Between β-Agonist Treatment and a Blockage of Sarcoplasmic Calcium Flow in a Rat Cancer Cachexia Model.

Busquets S, Castillejo M, Jove Q, Jude B, Mejias P, Lopez-Soriano F Onco Targets Ther. 2021; 14:1953-1959.

PMID: 33762827 PMC: 7982712. DOI: 10.2147/OTT.S293834.

References

Hinkle R, Hodge K, Cody D, Sheldon R, Kobilka B, Isfort R . Skeletal muscle hypertrophy and anti-atrophy effects of clenbuterol are mediated by the beta2-adrenergic receptor. Muscle Nerve. 2002; 25(5):729-734. DOI: 10.1002/mus.10092. View

Argiles J, Llovera M, Lopez-Soriano F . The role of cytokines in muscle wasting: its relation with cancer cachexia. Med Res Rev. 1992; 12(6):637-52. DOI: 10.1002/med.2610120605. View

Signorile J, Banovac K, Gomez M, Flipse D, Caruso J, Lowensteyn I . Increased muscle strength in paralyzed patients after spinal cord injury: effect of beta-2 adrenergic agonist. Arch Phys Med Rehabil. 1995; 76(1):55-8. DOI: 10.1016/s0003-9993(95)80043-3. View

Harvey K, Bothe Jr A, Blackburn G . Nutritional assessment and patient outcome during oncological therapy. Cancer. 1979; 43(5 Suppl):2065-9. DOI: 10.1002/1097-0142(197905)43:5+<2065::aid-cncr2820430714>3.0.co;2-1. View

Fuster G, Busquets S, Ametller E, Olivan M, Almendro V, De Oliveira C . Are peroxisome proliferator-activated receptors involved in skeletal muscle wasting during experimental cancer cachexia? Role of beta2-adrenergic agonists. Cancer Res. 2007; 67(13):6512-9. DOI: 10.1158/0008-5472.CAN-07-0231. View

Argiles J, Busquets S, Lopez-Soriano F . Cytokines as mediators and targets for cancer cachexia. Cancer Treat Res. 2006; 130:199-217. DOI: 10.1007/0-387-26283-0_9. View

Yang Y, McElligott M . Multiple actions of beta-adrenergic agonists on skeletal muscle and adipose tissue. Biochem J. 1989; 261(1):1-10. PMC: 1138772. DOI: 10.1042/bj2610001. View

Argiles J, Lopez-Soriano F . Why do cancer cells have such a high glycolytic rate?. Med Hypotheses. 1990; 32(2):151-5. DOI: 10.1016/0306-9877(90)90039-h. View

Argiles J, Alvarez B, Lopez-Soriano F . The metabolic basis of cancer cachexia. Med Res Rev. 1997; 17(5):477-98. DOI: 10.1002/(sici)1098-1128(199709)17:5<477::aid-med3>3.0.co;2-r. View

10.

van Royen M, Carbo N, Busquets S, Alvarez B, Quinn L, Lopez-Soriano F . DNA fragmentation occurs in skeletal muscle during tumor growth: A link with cancer cachexia?. Biochem Biophys Res Commun. 2001; 270(2):533-7. DOI: 10.1006/bbrc.2000.2462. View

11.

Toledo M, Busquets S, Sirisi S, Serpe R, Orpi M, Coutinho J . Cancer cachexia: physical activity and muscle force in tumour-bearing rats. Oncol Rep. 2010; 25(1):189-93. View

12.

Busquets S, Figueras M, Fuster G, Almendro V, Moore-Carrasco R, Ametller E . Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res. 2004; 64(18):6725-31. DOI: 10.1158/0008-5472.CAN-04-0425. View

13.

Mahler D . The effect of inhaled beta2-agonists on clinical outcomes in chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2002; 110(6 Suppl):S298-303. DOI: 10.1067/mai.2002.129703. View

14.

Rajab P, Fox J, Riaz S, Tomlinson D, Ball D, Greenhaff P . Skeletal muscle myosin heavy chain isoforms and energy metabolism after clenbuterol treatment in the rat. Am J Physiol Regul Integr Comp Physiol. 2000; 279(3):R1076-81. DOI: 10.1152/ajpregu.2000.279.3.R1076. View

15.

DeWys W . Management of cancer cachexia. Semin Oncol. 1985; 12(4):452-60. View

16.

Mersmann H . Overview of the effects of beta-adrenergic receptor agonists on animal growth including mechanisms of action. J Anim Sci. 1998; 76(1):160-72. DOI: 10.2527/1998.761160x. View

17.

Costelli P, Llovera M, Carbo N, Lopez-Soriano F, Agell N, Tessitore L . Muscle protein waste in tumor-bearing rats is effectively antagonized by a beta 2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway. J Clin Invest. 1995; 95(5):2367-72. PMC: 295859. DOI: 10.1172/JCI117929. View

18.

Wineski L, von Deutsch D, Abukhalaf I, Pitts S, Potter D, Paulsen D . Muscle-specific effects of hindlimb suspension and clenbuterol in mature male rats. Cells Tissues Organs. 2002; 171(2-3):188-98. DOI: 10.1159/000063712. View

19.

Kim Y, Sainz R . Beta-adrenergic agonists and hypertrophy of skeletal muscles. Life Sci. 1992; 50(6):397-407. DOI: 10.1016/0024-3205(92)90374-x. View

20.

Zangarelli A, Chanseaume E, Morio B, Brugere C, Mosoni L, Rousset P . Synergistic effects of caloric restriction with maintained protein intake on skeletal muscle performance in 21-month-old rats: a mitochondria-mediated pathway. FASEB J. 2006; 20(14):2439-50. DOI: 10.1096/fj.05-4544com. View